[Bortezomib].
Simons
S
S
Pharmazeutisches Institut, Klinische Pharmazie, Rheinische Friedrich-Wilhelms-Universität Bonn.
Scheulen
M E
ME
Jaehde
U
U
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001897:Boronic Acids / Q000737:chemistry / Q000627:therapeutic use*; D000069286:Bortezomib; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D007938:Leukemia / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy; D011480:Protease Inhibitors / Q000627:therapeutic use; D011719:Pyrazines / Q000737:chemistry / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib